Cardiovascular toxicity from therapies for light chain amyloidosis

P Morfino, A Aimo, V Castiglione, M Chianca… - Frontiers in …, 2023 - frontiersin.org
Amyloid light-chain (AL) amyloidosis is a hematological disorder characterized by abnormal
proliferation of a plasma cell clone producing monoclonal free light chains that misfold and …

Functional Status and Quality of Life in Light-Chain Amyloidosis: Advanced Imaging, Longitudinal Changes, and Outcomes

OF Clerc, S Vijayakumar, SAM Cuddy, G Bianchi… - JACC: Heart Failure, 2024 - Elsevier
Background In light-chain (AL) amyloidosis, whether functional status and heart failure–
related quality of life (HF-QOL) correlate with cardiomyopathy severity, improve with therapy …

[PDF][PDF] Survivorship among patients with haematological cancer: Work disability, dementia, and neuropathy

EF Maksten - 2023 - vbn.aau.dk
The studies included within this PhD thesis have been conducted during my employment at
the Department of Haematology, Aalborg University Hospital, from January 2020 to …